A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

Limited therapeutic options exist for the treatment of patients with triple negative breast cancer (TNBC). Neoadjuvant chemotherapy is currently the standard of care treatment in the early stages of the disease, although reliable biomarkers of response have been scarcely described. In our study we e...

詳細記述

保存先:
書誌詳細
出版年:Front Immunol
主要な著者: Pérez-Pena, Javier, Tibor Fekete, Janos, Páez, Raquel, Baliu-Piqué, Mariona, García-Saenz, José Ángel, García-Barberán, Vanesa, Manzano, Aránzazu, Pérez-Segura, Pedro, Esparis-Ogando, Azucena, Pandiella, Atanasio, Gyorffy, Balázs, Ocana, Alberto
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2019
主題:
Immunology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930158/
https://ncbi.nlm.nih.gov/pubmed/31921107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.02802
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料